Glycochenodeoxycholate and glycodeoxycholate 3‐O‐glucuronides, but not hexadecanedioate and tetradecanedioate, detected weak inhibition of OATP1B caused by GDC‐0810 in humans
British Journal of Clinical Pharmacology · 2023
DOI: 10.1111/bcp.15679 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Kenta Yoshida und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Glycochenodeoxycholic Acid, Glucuronides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Genentech.
Abstract (Originalsprache)
Endogenous biomarkers of drug transporters are promising tools to evaluate in vivo transporter function and potential alterations in the pharmacokinetics of their substrates. We have previously reported that coproporphyrin I/III captured the weak inhibition of OATP1B transporters by GDC‐0810. In this study, we measured plasma concentrations of additional biomarkers, namely fatty acids, bile acids and their sulphate or glucuronide conjugates in the presence and absence of GDC‐0810. Concentrations of hexadecanedioate and tetradecanedioate did not increase in the presence of GDC‐0810. Among bile acids and their conjugates, glycochenodeoxycholate and glycodeoxycholate 3‐O‐glucuronides (GCDCA‐3G and GDCA‐3G) showed C max increases with geometric mean ratio (95% confidence interval) of 1.58 (1.13‐2.22) and 1.49 (1.21‐1.83), consistent with previous reports from low‐dose rifampin co‐administration and pharmacogenetic studies. These results suggest that GCDCA‐3G and GDCA‐3G are two more promising biomarkers that may capture weak OATP1B inhibition in addition to coproporphyrin I/III.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.
- Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California, USA.
ORCID-Profile: Kenta Yoshida
Förderung
- Genentech
Zitieren
APA
Yoshida, K., Jaochico, A., Mao, J., & Sangaraju, D. (2023). Glycochenodeoxycholate and glycodeoxycholate 3‐O‐glucuronides, but not hexadecanedioate and tetradecanedioate, detected weak inhibition of OATP1B caused by GDC‐0810 in humans. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15679
Vancouver
Yoshida K, Jaochico A, Mao J, Sangaraju D. Glycochenodeoxycholate and glycodeoxycholate 3‐O‐glucuronides, but not hexadecanedioate and tetradecanedioate, detected weak inhibition of OATP1B caused by GDC‐0810 in humans. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15679
BibTeX
@article{Yoshida2023,
author = {Yoshida, Kenta and Jaochico, Allan and Mao, Jialin and Sangaraju, Dewakar},
title = {Glycochenodeoxycholate and glycodeoxycholate 3‐O‐glucuronides, but not hexadecanedioate and tetradecanedioate, detected weak inhibition of OATP1B caused by GDC‐0810 in humans},
journal = {British Journal of Clinical Pharmacology},
year = {2023},
doi = {10.1111/bcp.15679}
}
EUVIMED